CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron

 
• By Sten Stovall
  
cardiovascular system
Novartis said the CANTOS trial in inflammatory cardiovascular disease met the primary endpoint • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D